|
MechanismIL-12R stimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Enrolling by invitationPhase 1/2 Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma
Clinical study of a novel oncolytic virus Ad-TD-nsIL12 in the treatment of primary high-grade glioma
/ Enrolling by invitationPhase 1/2 A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of Recombinant Human NsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Patients with Recurrent/progressive High-grade Glioma.
This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) in patients with recurrent/progressive high-grade glioma.
/ Enrolling by invitationPhase 1 Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetics of Recombinant Human NsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Patients with Malignant Solid Tumors
This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.
100 Clinical Results associated with Beijing Bio-Targeting Therapeutics Technology
0 Patents (Medical) associated with Beijing Bio-Targeting Therapeutics Technology
100 Deals associated with Beijing Bio-Targeting Therapeutics Technology
100 Translational Medicine associated with Beijing Bio-Targeting Therapeutics Technology